RxDoctor Payments Data

Ashley Lane, MD

Family Medicine · Lineville, ALNPI 1649616194

Payments from drug & device makers

$4,361in general payments, 2019–2025

Across 218 payments — averaging $20.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • AstraZeneca$353
  • Amgen$351
  • Abbott$347
  • Novo Nordisk$327
  • Otsuka America Pharmaceutical, Inc.$181
  • plus $2K from 31 others

What the payments were for

  • Food & beverage$4,25498%
  • Other$1072%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,361 in reported general payments places this provider in the 80th percentile of 1,680 family medicine providers in Alabama.

See all family medicine providers in Alabama

Medicare billing

Part B allowed, 2024
$65,236
Medicare patients
208
Services billed
677

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide75$85,311
TrulicityDulaglutide64$74,383
MounjaroTirzepatide41$50,583
JardianceEmpagliflozin38$42,742
EliquisApixaban31$40,847
RybelsusSemaglutide18$23,876
LinzessLinaclotide22$19,632
JanuviaSitagliptin Phosphate14$19,151
EntrestoSacubitril/Valsartan13$17,893
FarxigaDapagliflozin Propanediol15$17,659
MyrbetriqMirabegron17$12,792
BrilintaTicagrelor18$12,768
GemtesaVibegron24$11,564
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog20$8,558
Trelegy ElliptaFluticasone/Umeclidin/Vilanter13$8,074

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$143$124,965105 claims
Novo NordiskOzempic, Rybelsus$327$109,18793 claims
Boehringer IngelheimJardiance$56$42,74238 claims
AstraZenecaFarxiga, Brilinta$353$30,42733 claims
AbbVieLinzess, Synthroid$1,195$21,34243 claims
NovartisEntresto$144$17,89313 claims
GSKTrelegy Ellipta$142$8,07413 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,680 family medicine providers in Alabama.

Other family medicine in Lineville

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →